Skip to main content

ambrisentan (Volibris®)

 

Status: Recommended

Ambrisentan (Volibris®) is recommended as an option for use within NHS Wales for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue.

Ambrisentan (Volibris®) is recommended as an option for use within NHS Wales, for the treatment of PAH in adolescents and children (aged 8 to less than 18 years) of WHO FC II to III including use in combination treatment. Efficacy has been shown in IPAH, familial, corrected congenital and in PAH associated with connective tissue disease.

 Final recommendation: ambrisentan (Volibris) 4819 (PDF, 421Kb)

Medicine details

Medicine name ambrisentan (Volibris®)
Formulation 2.5 mg, 5 mg, 10 mg film-coated tablet
Reference number 4819
Indication

Treatment of PAH in adolescents and children (aged 8 to less than 18 years) of WHO Functional Class (FC) II to III including use in combination treatment. Efficacy has been shown in IPAH, familial, corrected congenital and in PAH associated with connective tissue disease

Company GlaxoSmithKline UK
BNF chapter Cardiovascular system
Submission type Licence extension for paediatric use
Status Recommended
Advice number 2022
AWMSG meeting date 18/10/2022
Date of issue 07/11/2022
Further information

This advice incorporates and replaces the AWMSG recommendation for ambrisentan (Volibris®) for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment. (advice number 2508, originally published 2009).

The additional sentence ‘Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease’ is added to reflect the change in the wording of the licensed indication.

Follow AWTTC: